The optimal cut-off value for visfatin for the detection of subclinical atherosclerosis in patients undergoing unknown treatments was 1.41 ng/mL (63% sensitivity; 60% specificity; p = 0.010). This evidence concerns the gene NAMPT and atherosclerosis.